Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant cemiplimab versus placebo after surgery and radiation in high-risk cutaneous squamous cell carcinoma
2019-000566-38Phase 3Unknown
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cutaneous squamous cell carcinoma (cSCC) comparing Cemiplimab with Placebo (2 arms). Primary endpoint: Disease-free survival. Status: unknown.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2019-000566-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000566-38.